1-4 of 4
Markus Löffler
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

SOCS1 Mutation Subtypes Predict Divergent Outcomes in DLBCL Patients

Jochen K Lennerz, MD, PhD, Birgit Schif, Christian W Kohler, PhD, Stefan Bentink, PhD, Markus Kreuz, Ingo Melzner, PhD, Lorenz Trümper, Markus Löffler, MD, Rainer Spang, Peter Moeller, MD
Journal: Blood
Blood (2012) 120 (21): 419.
https://doi.org/10.1182/blood.V120.21.419.419
Published: 2012
Journal Articles

Improved Outcome of Elderly Poor-Prognosis DLBCL Patients with 6xCHOP-14 and 8 Applications of Rituximab (R) Given Over An Extended Period: Results of the SMARTE-R-CHOP-14 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)

Michael Pfreundschuh, MD, Gerhard Held, Samira Zeynalova, Viola Pöschel, Andreas Viardot, MD, Matthias Hänel, MD, Ulrich Keller, MD, Marcel Reiser, MD, Markus Löffler, Niels Murawski, MD
Journal: Blood
Blood (2011) 118 (21): 592.
https://doi.org/10.1182/blood.V118.21.592.592
Published: 2011
Journal Articles

Randomised Intergroup Trial of First line Treatment for young Low-Risk Patients (<61 years) with Diffuse Large B-Cell Non-Hodgkin's Lymphoma (DLBCL) with a CHOP-like Regimen with or without the Anti-CD20 Antibody Rituximab – 6-Year Follow-up of the Mint Study of the Mabthera International Trial (MInT) Group

Michael Pfreundschuh, MD, Evelyn Kuhnt, Lorenz Trümper, MD, Anders Osterborg, MD, PhD, Marek Trneny, MD, Lois Shepherd, MD, Devinder S Gill, MD, Jan Walewski, MD, Ruth Pettengell, FRACP, PhD, Ulrich Jäger, MD, Pier Luigi Zinzani, MD, PhD, Ofer Shpilberg, MD, MPH, Stein Kvaloy, MD, Mads Hansen, MD, Rolf Stahel, MD, Noel Milpied, MD, Armando Lopez-Guillermo, MD, Sandra Grass, MD, Niels Murawski, MD, Viola Pöschel, Markus Löffler
Journal: Blood
Blood (2010) 116 (21): 111.
https://doi.org/10.1182/blood.V116.21.111.111
Published: 2010
Journal Articles

The Role of the Rituximab Partner Chemotherapy Regimen In Young Patients with Good-Prognosis Diffuse Large B-Cell Lymphoma (DLBCL): Results of the 6-Year Follow-up of the Mint Study of the Mabthera International Trial (MInT) Group.

Niels Murawski, MD, Evelyn Kuhnt, Sandra Grass, MD, Wolfgang Hiddemann, MD, Eva Cavallin-Stahl, MD, Georg Hess, MD, Mathias Witzens-Harig, Ingrid Vasova, MD, Ulrich Jäger, MD, Michal Osowiecki, MD, Scott North, MD, Ruth Pettengell, FRACP, PhD, Viola Pöschel, Markus Löffler, Michael Pfreundschuh, MD
Journal: Blood
Blood (2010) 116 (21): 2826.
https://doi.org/10.1182/blood.V116.21.2826.2826
Published: 2010